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Abstract
Aims—The enzyme catechol-O-methyl transferase (COMT) plays a primary role in the 
metabolism of catecholamine neurotransmitters and is implicated in the modulation of cognitive 
and emotional responses. The best-characterized single nucleotide polymorphism (SNP) of the 
COMT gene consists of a valine (Val)-to-methionine (Met) substitution at codon 108/158. The 
Met-containing variant confers a marked reduction in COMT catalytic activity. We recently 
showed that the activity of recombinant COMT is positively regulated by the enzyme Met 
sulfoxide reductase (MSR), which counters the oxidation of Met residues of proteins. The current 
study was designed to assess whether brain COMT activity may be correlated to MSR in an allele-
dependent fashion.
Methods—COMT and MSR activities were measured from post-mortem samples of prefrontal 
cortices, striata and cerebella of 32 subjects, by using catechol and dabsyl-Met sulfoxide as 
substrates, respectively. Allelic discrimination of COMT Val108/185Met SNP was performed using 
the Taqman 5’nuclease assay.
Results—Our studies revealed that, in homozygous carriers of Met, but not Val alleles, the 
activity of COMT and MSR were significantly correlated throughout all tested brain regions.
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Discussion—These results suggest that the reduced enzymatic activity of Met-containing 
COMT may be secondary to Met sulfoxidation, and point to MSR as a key molecular determinant 
for the modulation of COMT activity.
Keywords
Postmortem human brain; Met oxidation; Catechol-O-methyltransferase; Gene polymorphism; 
Oxidative stress
INTRODUCTION
Catechol-O-methyltransferase, a key enzyme serving the inactivation of dopamine and 
norepinephrine [1, 2], is encoded by the COMT gene. The differential transcription of 
COMT leads to two isoforms of COMT with similar catalytic mechanisms, but divergent 
cellular localization and substrate affinity [2–6]: a cytosolic soluble form (S-COMT) and a 
membrane-bound form (MB-COMT), containing an N-terminal, membrane-anchor region 
with 50 additional amino acids [5, 7, 8]. The best-characterized single nucleotide 
polymorphism of COMT, rs4680, features the substitution of a valine (Val) for a methionine 
residue (Met) [9] at positions 108 of S-COMT and 158 of MB-COMT (Val108/158Met) [10]. 
The Met variant has been shown to exhibit lower enzymatic activity, resulting in reduced 
catecholamine metabolism and behavioral alterations, including decreased vulnerability for 
cognitive deficits [11–14] and higher predisposition for aggression in vulnerable individuals 
[15, 16, 17; see 18 for conflicting results].
Several lines of research have investigated the symptomatic correlates of this polymorphism 
in schizophrenia and bipolar disorder (BD) [19, 20]. Notably, the Met variant is associated 
with a slightly lower risk for negative and cognitive symptoms of schizophrenia [21–27], but 
a greater severity of mania-related symptoms [28–31].
The Val108/158Met substitution has been shown to reduce the thermostability of the COMT 
enzyme and decrease its activity without affecting its structural properties [10, 32, 33]. 
Further, this substitution affects protein expression, but not mRNA expression levels, 
indicating that this polymorphism may lead to post-translational changes in the protein [33, 
34]. Nevertheless, the molecular underpinnings of these changes are not fully understood. 
Given that Met residues undergo spontaneous oxidation into Met sulfoxide, we hypothesized 
that this process may contribute to the reduction in activity observed in the Met variant. 
Indeed, we have recently showed that the activity of the recombinant Met108/158 variant was 
increased by Met sulfoxide reductase (MSR) type A (MSR-A) [35]. The enzymatic 
reduction of the S- and R- enantiomers of Met sulfoxide is mediated by MSR-A and MSR 
type B (MSR-B), respectively, and may affect protein function and stability [36, 37]. 
Accordingly, in this study we tested the activities of COMT and MSR in postmortem brain 
tissues of schizophrenia and BD patients, as well as non-affected controls, and analyzed this 
relation with respect to the Val108/158Met genotypes.
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Postmortem brain tissues from ten (7 males and 3 females) schizophrenia/ schizoaffective 
disorder patients, thirteen (8 males and 5 females) BD patients and nine (6 males and 3 
females) normal (without psychopathology at time of death or significant medical illnesses) 
control subjects were obtained from the Southwest Brain Bank, Department of Psychiatry, 
University of Texas Health Science Center at San Antonio, with consent from the next-of-
kin. All demographic and clinical characteristics of the individuals are described in Table 1. 
The three groups did not significantly differ by age at death, postmortem intervals (PMI) 
(20–45 h) and pH (Table 1).
The Southwest Brain Bank collection of postmortem tissues for research is conducted under 
the jurisdiction of the State of Texas Anatomical Review Board and the UTHSCSA 
Institutional Review Board regulates the interviews with the next-of-kin [38]. Trained 
clinicians interview the next-of-kin about the donor and conduct a DSM-IV-based Mini-
International Neuropsychiatric Interview (MINI) [39] to identify Axis 1 and the Structured 
Clinical Interview for DSM-IV Personality Disorder [40, 41] for Axis 2 psychopathology. 
Diagnoses were determined by expert diagnostician group consensus (MINI inter-rater 
reliability = 0.8) after review of the interview materials and available medical records.
Intact fresh brains were transported to the Southwest Brain Bank, and the cerebrum was 
hemisected. Each hemisphere was cut into 1-cm thick coronal blocks and immediately 
frozen in 2-methylbutane (Fisher Scientific Co, Fair Lawn, NJ), and stored at −80°C. All 
tissue samples were analyzed by a neuropathologist, and found to be free of any 
confounding gross and microscopic neuropathology. The following brain regions were 
dissected from the right hemisphere: PFC (corresponding to Brodmann area 9); dorsal 
striatum (rostral caudate); and cerebellum (lateral cerebellar cortex) [38]. The selected brain 
regions were homogenized in the presence of 25mM Tris-HCl, pH, 7.4 and protease 
inhibitors cocktail (Roche and Life Technologies, Indianapolis, IN, USA) at 4°C. Following 
centrifugation at 10,000 g for 20 minutes, the supernatants were collected and stored at 
−80°C for future analyses.
COMT rs4680 genotyping
Genomic DNA was extracted from brain tissue using the Puregene DNA purification kit 
(Gentra, Minneapolis, MN). Allelic discrimination for the COMT Val108/185Met SNP was 
performed using the Taqman 5’nuclease assay (SNP ID rs4680, Life Technologies, Grand 
Island, NY, USA). Genotypes were determined using the ABI 7900HT SDS 2.2.2 software 
adapted in the ABI 7900HT Sequence Detection System.
Enzymatic activity assay for MSR
MSR activity was measured in cell extracts of the postmortem brains as previously 
described [42, 43]. Briefly, equal protein amounts of each tissue/cell preparation (measured 
by Bio-Rad assay) were assayed for MSR activity following incubation in a reaction mixture 
containing 25mM Tris-HCl, pH, 7.4, 20mM dithiothreitol (DTT), and 200µM dabsyl-Met 
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sulfoxide (total final volume of 100µl) for 30 minutes at 37°C. Then, the reaction was 
stopped by the addition of 100 µl of acetonitrile. Proteins in each sample were precipitated 
by a short high-speed centrifugation, and the soluble material was analyzed for the presence 
of dabsyl-Met following HPLC-based chromatographically separation using C-18 column 
(Phenomenex, Torrance, CA). MSR activity was expressed as pmol dabsyl-Met formed per 
mg protein per minute.
Enzymatic activity assay for COMT
Postmortem human brain sections were homogenized as described above and their COMT 
activity was monitored according to established procedures [26, 44, 45] with minor 
modifications. Briefly, the 3,4-dihydroxybenzoic acid was used as a catechol substrate to 
determine the level of COMT- dependent methylation activity. One hundred micrograms of 
protein from brain extracts or one microgram of pure recombinant S-COMT were added to a 
final volume of 100 µl of reaction mixture containing: 25mM Tris-HCl, pH 7.4, 1 mM 
MgCl2, 2.8 µM radioactive S-adenosyl-Met (3H-SAM, 80.7Ci/mMol) (Perkin-Elmer, 
Waltham, MA), 20 µM non-radioactive SAM, 1 mM 3,4- dihydroxybenzoic acid, 2.0 mM or 
20mM DTT as indicated, and 0.7 units of adenosine deaminase. The 2mM and 20 mM 
concentrations of DTT were used to reduce either cysteine residues alone or both cysteine 
and Met residues of S-COMT. Accordingly, 20mM DTT was routinely used when 
measuring S-COMT activity, unless indicated otherwise. The reaction mixture was 
incubated for 20 minutes at 37°C and the reaction was stopped by the addition of 100 µl of 2 
N HCl and 200 µl of ethyl acetate. Samples were then vortexed and centrifuged at 10,000×g 
for 5 min. Then, 100 µl of the top ethyl acetate layer was mixed with 10ml of scintillation 
fluid and counted for the 3H-methylated catechol product. S-COMT activity was expressed 
as pmol 4-hydroxy-3-methoxybenzoic acid (HMBA) formed per mg protein per minute. 
Given that MSR enzymes are soluble proteins, all analyses on COMT activities were 
performed on S-COMT, so as to obtain both enzymes from the same soluble cell fraction 
and maintain reliable and accurate activity correlations.
Statistical analyses
The frequency of COMT Val108/158Met variants was compared across diagnostic groups by 
Chi-square (χ2) test. Normality and homoscedasticity of data distribution were verified using 
Kolmogorov-Smirnov and Bartlett’s tests. Comparisons between diagnostic groups and 
genotypes were performed by ANOVAs, followed by Tukey’s test with Spjøtvoll-Stoline 
corrections for post-hoc comparisons. Homogeneity-of-slopes ANCOVA designs were used 
to test for interactions between continuous and categorical predictors. In the absence of 
significant interactions, correlation analyses were performed by multiple regressions. 
Significance threshold was set at 0.05. In consideration of the objections to the conceptual 
limits of Bonferroni corrections for multiple testing [46], significant values were reported 
uncorrected throughout the study. All statistical analyses were performed by STATISTICA 
9 (Statsoft, Tulsa, OK).
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Differences in COMT and MSR activities across diagnostic groups, genotypes and genders
Following genotyping of all subjects, we assessed that the distribution of COMT 
Val108/158Met genotypes did not differ across diagnostic groups (χ2 =5.26, df= 4, P=0.26, 
NS; Table 2). Furthermore, the overall genotype distribution was in accordance with Hardy-
Weinberg equilibrium, with a predicted frequency of the Val and Met alleles of 0.52 and 
0.48, in line with previous data in North American individuals of European origin [47, 48]. 
We then analyzed the differences in brain-regional COMT and MSR activities between 
controls, schizophrenia and BD subjects, across the three Val108/158Met genotypes. All 
values are reported in Table 2. No significant differences in either COMT or MSR activities 
were observed with respect to genotype. In regards to diagnostic groups, as shown in Fig. 
1C, ANOVA detected a significant increase in cerebellar MSR activity in samples from BD-
affected subjects (F(2,28)=14.65; P<0.0001), in comparison with both controls (P<0.01) and 
schizophrenia patients (P<0.001). The increase in MSR activity was not specific to any 
genotype. No other significant difference was found in MSR activity in the PFC and 
striatum (Fig.1A–B). Furthermore, COMT activities were not significantly different in any 
of the tested regions (Fig, 1D–F). Gender-specific comparisons revealed that, in comparison 
with males, female subjects had a significant increase in MSR activity in the striatum 
(F(1,30)=4.75, P=0.04), but not in any other region (data not shown).
Correlations of COMT and MSR activities
We then analyzed the link between COMT and MSR activities in each of the three tested 
brain regions, across different diagnostic groups and genotypes. A preliminary 
homogeneity-of-slope ANCOVA design revealed no significant interactions among COMT 
activity (dependent variable) and any of the following variables: MSR activity, age, PMI, 
BMI brain pH (continuous variables), as well as ethnicity, suicidal death, smoking, alcohol 
dependence and gender (categorical dichotomous variables), across all three regions, 
diagnostic groups and genotypes.
In the PFC (Fig.2A), COMT activity was robustly correlated with MSR activity 
(F(1,28)=23.97; P<0.0001; R2=0.46). Similar correlations were found for cortical samples 
of Met/Met (P<0.05; R2=0.73) and Met/Val (P<0.0001; R2=0.70) subjects (Fig. 2B–C); 
however, MSR and COMT activities were not significantly correlated in the PFCs of 
Val/Val individuals (Fig. 2D). As shown in Fig. 3A–D, the correlation of COMT and MSR 
was identified across the PFCs of all diagnostic groups.
In the striatum, COMT and MSR activities were also found to be mildly, yet significantly 
correlated (F(1,29)=5.49; P=0.03; R2=0.16) (Fig. 2E). The analysis of this correlation across 
different genotypes revealed significant effects only in the Met/Met group (F(1,5)=16.15; 
P=0.01; R2=0.76) (Fig. 2F), but not in either Met/Val or Val/Val subjects (Fig.2G–H). The 
correlation between COMT and MSR was found in the striata of both controls (Fig. 3F) and 
schizophrenia subjects (Fig. 3G), but not in BD individuals (Fig. 3H).
In the cerebellum, overall COMT activity was not significantly correlated with MSR activity 
(F(1,28)=5.49; P=0.10; R2=0.10) (Fig. 2I); however, similar to the striatum, a robust 
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correlation between these enzyme activities was identified in the Met/Met group 
(F(1,4)=21.18; P=0.01; R2=0.84) (Fig. 2J), while no significant correlation was found in 
either Met/Val or Val/Val subjects (Fig.2K–L). Furthermore, cerebellar MSR and COMT 
activities were not significantly correlated in any diagnostic group (Fig. 3I–L).
DISCUSSION
The results of this study showed that, in homozygous carriers of Met, but not Val 108/158 
COMT allele, COMT enzyme activity was robustly correlated with MSR across all tested 
brain regions. In addition, COMT and MSR activities were also correlated in the PFC (but 
not other brain regions) of Met/Val carriers. These data support our recent findings on the 
ability of MSR type A to completely restore the activity of the Met108 variant in the absence 
of oxidative conditions [35]. Collectively, the results of these and our previous analyses 
suggest that the sulfoxidation of the Met108/158 residue is primarily responsible for the 
reduction in enzyme activity observed in this variant (Fig. 4). In line with this interpretation, 
Cotton and colleagues [49] reported the involvement of cysteine, the other sulfur-containing 
amino acid, in the greater susceptibility of the Met108/158 variant to oxidation.
Previous findings have shown that the Met108/158 variant confers lower thermo-stability to 
COMT, which results in greater vulnerability to proteolytic degradation and reduced protein 
expression [32, 33]. Several findings support that these phenomena may be contributed by 
the sulfoxidation of the Met108/158 residue. Indeed, Met oxidation has been shown to alter 
the hydrophobicity of proteins [50], resulting in conformational changes [51] and higher 
vulnerability to protease-mediated digestion [52].
It is worth noting that our previous study documented that the enhancement of COMT 
catalytic activity following addition of MSR-A was observed in both the Met and Val –
containing variants after exposure to stress conditions, suggesting that other Met sulfoxide 
residues in the primary sequence of COMT may also be targeted by MSR [35]. Given that 
the degree of sulfoxidation of other Met residues on the Met108/158 genotype has yet to be 
determined, this possibility could not be directly verified in the present study; however, the 
lack of correlations betw een MSR and COMT in homozygous Val carriers suggests that the 
oxidation of other Met residues in COMT may need to be accompanied by Met108/158 
variant in order to be influential on the catalytic characteristics of this enzyme in vivo.
In substantial agreement with prior evidence [47, 53–58], we failed to identify an association 
between COMT alleles and either schizophrenia or BD. Nevertheless, studies have indicated 
a potential association between schizophrenia and polymorphisms within MSRA gene [59]. 
Thus, epistatic relationships between MSRA and COMT genes may be critical in the 
functional regulation of catecholamine levels in the PFC and striatum, and play a role in 
vulnerability for specific behavioral deficits, at least with respect to schizophrenia. An 
alternative possibility may be that the current diagnostic constructs for schizophrenia and 
BD may not be adequate to match potential alterations underlying these conditions.
Another important finding of our study was that samples from BD subjects displayed a 
significant increase in cerebellar MSR activity. Cerebellar atrophy, blood flow reductions 
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and other signs of pathology have been consistently associated with BD [60–67] and 
secondary mania [9, 68, 69]. Interestingly, cerebellar deficits in BD have been shown to 
become more prominent with illness progression (63, 68, 69), suggesting that the observed 
increase in MSR activity in the cerebellum of BD subjects may be secondary to aging-
dependent processes, in view of the well-documented action of this enzyme in the protection 
from these phenomena [36, 70, 71]. In keeping with this idea, cerebellar expression of MSR-
A is among the highest in adult humans [72], underscoring the importance of this enzyme in 
the neuroprotection of this brain region.
This study includes a number of limitations. First, the sample size does not allow for the 
analysis of complex interactions between genotype and gender across different diagnostic 
groups, or for the evaluation of potential effects of medications on COMT and MSR 
activities, which may have interfered with some of the observed correlations. Second, due to 
our sample size, our analyses could not confirm the impact of COMT genotype on the 
activity of this enzyme; nevertheless, in keeping with previous post-mortem data collected 
on larger samples [33], we found that both normal and schizophrenia-affected Met/Met 
carriers exhibited marked numerical reductions in COMT activity in comparison with their 
Val/Val counterparts, across all brain regions (Table 2). Third, our analyses of COMT 
activity were based on S-COMT, in order to maintain reliable correlations with MSR (which 
is also cytosolic). Although both enzymes display approximately equal amounts and activity 
[73], S-COMT is less important in catecholamine inactivation than MB-COMT [6, 33, 74]. 
Nevertheless, it is likely that the results obtained on S-COMT can be generalized to MB-
COMT, given their similar catalytic activity [2] and the intracellular localization of MB-
COMT [8]; in addition, it should be noted that the action of MSR is based on the availability 
of Met sulfoxide residues, rather than the specific identity of the protein target. Thus, the 
action of MSR on S- and MB-COMT should be predictably similar.
These limitations notwithstanding, the present study has highlighted that the actual relation 
between Met-harboring variants and the reduction in enzyme activity is likely moderated by 
sulfoxidation of the Met residue, which is directly influenced by MSR. Future studies are 
required to fully clarify the relationship between COMT and MSR, and its relevance with 
respect to emotional regulation and the pathophysiology of mental disorders.
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Figure 1. Enzymatic activities of Msr and COMT in human brain regions
Differences in MSR (A–C) and COMT (D–F) catalytic activities between post-mortem 
human tissue samples from the prefrontal cortex, striatum and cerebellum of controls (CTL), 
schizophrenia subjects (SCZ) and bipolar disorder subjects (BD). Values are displayed as 
means ± SEM. All analyses were run by 1-way ANOVAs. **, P<0.01 in comparison with 
controls; ###, P<0.001 in comparison with schizophrenia subjects.
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Correlations of MSR and COMT catalytic activities in post-mortem human tissue samples 
from the (A–D) prefrontal cortex, (E–H) striatum and (I–L) cerebellum across different 
Val108/158Met COMT genotypes. Empty lozenges, Met/Met carriers; Grey lozenges, Met/Val 
carriers; Black lozenges, Val/Val carriers.
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Correlations of MSR and COMT catalytic activities in the (A–D) prefrontal cortex, (E–H) 
striatum and (I–L) cerebellum of controls, schizophrenia subjects and bipolar disorder 
subjects. Empty circles, controls; Grey circles, schizophrenia subjects; Black circles, bipolar 
disorder subjects.
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Hypothetical relation between MSR and COMT in relation to the post-translational changes 
of Met108/158-containing COMT variant.
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Table 1
Characteristics of subjects
Criteria Controls Schizophrenia Bipolar
disorder
Number 9 10 13
Mean death age ± SEM 51.56 ± 5.08 54.3 ± 1.81 45.77 ± 2.70
Median death age 54 53 45
Age range 20–67 49–64 25–62
% Suicides 0.00% 20.00% 69.23%
% Smokers 30.00% 70.00% 80.00%
% Alcohol-dependents 0.00% 10.00% 30.77%
Race/ethnicity
Caucasians 77.78% 60.00% 84.61%
Hispanics 22.22% 40.00% 15.39%
Gender
Males 66.67% 70.00% 61.54%
Females 33.33% 30.00% 38.46%
Other characteristics
pH 6.48 ± 0.05 6.23 ± 0.14 6.56 ± 0.04
Postmortem intervals, PMI 26.06 ± 1.11 29.98 ± 2.21 28.22 ± 1.78
Body mass index, BMI 27.93 ± 2.24 29.73 ± 1.23 26.34 ± 1.92
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